Offered HIPEC today, completely unexpected! In a joyful tailspin!!!

Us palliative, incurable ghosts, generally say YES PLEASE when offered curative surgery.

I did today as well, from Australia top hipec surgeon, and one of the best in the world. so then I am rushed off to the hipec onc, then back to see the hipec nurse.

thespleenecomy is a big worry!!!!!!!!!!!!!! what about future dc, even vogl was focused on saving my spleen and he is not even an immunotherapist.

But of course I say yes, I have no money today for any treatments, and I am still waiting on the markers. thect scan was pretty fantastic, just a little disease.

i asked in I can have a little german holiday, trip 8 to do a tace and preop dc and my usual bag of tricks. i do want to hammer this last remaining, visible little peritional met, its on the surface of the liver, before the full hipec.

http://www.nature.com/mt/journal/v21/n7/full/mt201380a.html dc and brain mets, an interesting read
Finally, when discussing treatment efficacy and success of new clinical strategies, it is important to bear in mind the current prognosis and treatment options available for glioma patients. While the results of the CAR-CD19 trial showed that two out of the three CLL patients are in remission for over a year, which is extraordinary, one must realize that with a median survival of 8–10 years, the CLL population is not comparable to glioma patients. We advocate that in a patient population where the 2-year survival rate is only 40%, and in the past 25 years the median survival rate has only increased by 3 months, our expectation on efficacy should be as equally moderate.^1,2 Furthermore, a gain of months rather than years should be valued as well as the decrease in side effects and/or increase in patient’s well-being. The aim of trials should therefore not only be directed towards increased survival, but also for better quality-of-life. It is the hope that optimization of some of the strategies discussed here would increase both potential goals and expectations. For now, it is difficult to conclude what role and effectimmuno-cellular therapy has on malignant gliomas. If some of the discussed issues can be addressed, and current clinical trials show promising results, this therapeutic strategy has potentially a tremendous value in the search for a cure for tumors as heterogeneous as GBM while complementing current standard therapy.

http://jco.ascopubs.org/content/30/4/445.full#sec-8 immunotherapies and mm, but the concepts apply all cancers.
Our ongoing efforts include the development of immune (vaccine and adoptive immunotherapy) strategies, development of novel agents targeting the MM cell in the BM microenvironment, development of rationally based multiagent combination therapies, and use of genomics to improve both patient classification and allow for personalized medicine in MM. With this continued rapid evolution of progress, MM will be a chronic illness with sustained complete responses in a significant fraction of patients.

http://intimm.oxfordjournals.org/content/24/7/455.full using tumeric/curcumin to control dc excessive inflamation!
EF24, 3,5-bis(2-fluorobenzylidine)-4-pyperidone, is a synthetic analog of curcumin (16, 17). Synthetic curcuminoids are being developed because they are more potent and better bioavailable than curcumin (18, 19). EF24 was first developed as a tumor suppressant by a group of researchers in Emory University, Atlanta, GA, USA (17). We hypothesize that the effective inhibition of NF-κB signaling by EF24 extends its therapeutic application to a variety of NF-κB-dependent disorders, including inflammation (20). In this work, we investigated the immunopharmacology of EF24 in a DC model. We show that EF24 suppresses LPS-induced DC maturation, NF-κB activity and secretion of pro-inflammatory cytokines. The observations held true in the primary bone marrow derived DCs as well. The results are suggestive of the potential of EF24 as a novel agent for managing DC-mediated exaggerated inflammatory conditions.